Retatrutide vs Semaglutide
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Semaglutide (Ozempic). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Retatrutide is the drug that made Ozempic look like a warm-up act. In the TRIUMPH-4 Phase 3 readout Eli Lilly shared in December 2025, patients on the 12mg dose lost an average of 28.7% of body weight over 68 weeks of treatment. Semaglutide, the molecule that built the entire GLP-1 category, still sits around 15% in its Wegovy label. That gap is not subtle. It is roughly the difference between losing 30 pounds and losing 60 pounds on a 200-pound frame, and it has rewritten the ceiling for what obesity pharmacotherapy can do.
But semaglutide has two things retatrutide does not yet: an FDA approval and years of track record. Wegovy is approved for chronic weight management, MASH (since August 2025), and cardiovascular risk reduction through the SELECT trial. Novo Nordisk launched oral Wegovy in January 2026 at $149 per month self-pay, which is suddenly the cheapest route to a GLP-1 prescription in the US. Retatrutide is still an investigational compound. Lilly expects to file the NDA in late 2026, which puts the earliest realistic prescription availability somewhere in the second half of 2027.
There is also a safety wrinkle worth knowing. Retatrutide introduced a side effect GLP-1 veterans have not seen before: dysesthesia, reported by 20.9% of patients at the 12mg dose, along with 18.2% overall discontinuation. Semaglutide's side effect profile is well-mapped after years of real-world use, mostly GI, mostly manageable with dose titration. The table below breaks down the specifics on mechanism, dosing, cost, and current FDA status for both compounds.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Semaglutide Ozempic, Wegovy |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | FDA Approved |
| Category | Weight Loss | Weight Loss |
| Primary Use | Obesity and weight management | Type 2 diabetes, chronic weight management, and MASH |
| Weight Loss % | 28.7% | 15% |
| Monthly Cost | $1,200 - $1,500/mo | $1,000 - $1,400/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 2.4mg weekly (Wegovy dose) |
| Frequency | Weekly | Weekly |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Phase 3 | Approved |
Key Differences
- 1Semaglutide is FDA-approved, while Retatrutide is currently phase 3 (nda expected late 2026).
- 2Retatrutide showed 28.7% average weight loss in trials compared to 15% for Semaglutide.
- 3Semaglutide is generally more affordable ($1,000 - $1,400/mo) compared to Retatrutide ($1,200 - $1,500/mo).
Which Is Better For...
Semaglutide
Those seeking an FDA-approved treatment with established safety data
Retatrutide
Maximum weight loss efficacy based on clinical trial data
Semaglutide
More budget-friendly option with lower monthly costs
Semaglutide
Fewer commonly reported side effects
If you want the strongest weight-loss drug ever tested in humans and you can wait until 2027, retatrutide is the one to watch. If you want something you can actually fill at a pharmacy this week, semaglutide is the answer, and the new oral Wegovy at $149 per month has finally made it affordable without insurance. Retatrutide's 28.7% weight loss is genuinely category-defining, but a Phase 3 readout is not a pharmacy shelf, and clinical experience with the dysesthesia signal is still limited. For most people asking this question right now, the honest recommendation is semaglutide today, retatrutide on the watchlist for 2027.
Get Retatrutide or Semaglutide Online
Vetted telehealth providers that prescribe either peptide.
PeptideVS may earn a commission from providers listed below. Our editorial data is independent - see our disclosure for details.
Henry Meds
Sponsored
Compounded GLP-1 therapy with flat monthly pricing and no insurance hassle.
- Flat monthly price, no insurance required
- Compounded semaglutide and tirzepatide
- Licensed providers in 50 states
We may earn a commission when you sign up.
Mochi Health
Sponsored
Obesity-medicine-trained clinicians and a care team built around women.
- Obesity-medicine-trained MDs and RDs
- Compounded and brand-name GLP-1 options
- Insurance-aware pricing and savings tools
We may earn a commission when you sign up.
Found Health
Sponsored
Weight-care program combining GLP-1s with behavior coaching and nutritionists.
- Whole-person program, not just a prescription
- Insurance-first with cash-pay fallback
- Nutrition and habit coaching included
We may earn a commission when you sign up.
Ro Body
Sponsored
Brand-name Wegovy and Zepbound plus compounded options, handled end to end.
- Brand-name and compounded GLP-1 paths
- Insurance navigation built into intake
- Nationwide telehealth with ongoing check-ins
We may earn a commission when you sign up.
Hers Weight
Sponsored
GLP-1 injections paired with behavior coaching for long-term weight care.
- Compounded GLP-1 with licensed providers
- Coaching and habit support in-app
- Transparent monthly pricing
We may earn a commission when you sign up.
PlushCare
Sponsored
Primary-care telehealth with broad Rx coverage and same-day appointments.
- Broad primary-care scope, not GLP-1-only
- Same-day video visits in all 50 states
- Works with insurance for most plans
We may earn a commission when you sign up.
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Eli Lilly has said it expects to file the New Drug Application in late 2026 based on the TRIUMPH-4 Phase 3 data released in December 2025. Standard FDA review runs 10 to 12 months, so the earliest realistic approval timeline is the second half of 2027. Until then, retatrutide is only available through clinical trials or research suppliers, and it has no legal path to a prescription.
In head-to-head trial data, retatrutide at 12mg produced 28.7% average weight loss over 68 weeks, compared to semaglutide's roughly 15% in its Wegovy pivotal trials. That is almost double. The caveat is these are different trials with different populations, so a true head-to-head would narrow the gap. Lilly has not yet run a direct comparison study.
Dysesthesia is an abnormal, often unpleasant skin sensation - tingling, burning, or prickling without an external cause. In the TRIUMPH-4 Phase 3 data, 20.9% of patients on the 12mg retatrutide dose reported it, along with 18.2% overall discontinuation. It is a new adverse event profile that was not flagged in the GLP-1 class before. Lilly has not yet published a mechanism.
Yes. Novo Nordisk launched oral Wegovy in January 2026 at $149 per month through direct-to-consumer self-pay, compared to roughly $1,349 per month list for the injectable. It is the same active ingredient but a higher daily dose to account for lower oral bioavailability. For people without insurance coverage for GLP-1s, the oral version is now the most affordable legitimate path to semaglutide in the US.
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. They differ in FDA approval status, efficacy data, and cost.
In clinical trials, Retatrutide showed greater average weight loss (28.7%) compared to Semaglutide (15%). Individual results may vary.
Retatrutide typically costs $1,200 - $1,500/mo, while Semaglutide costs $1,000 - $1,400/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). Semaglutide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideSemaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metab...
View Full Semaglutide GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Semaglutide should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.